People · Operator
Named in public records as an officer, director or promoter · active 2009–2021 · Medical Devices, Telecommunications, Pharmaceuticals, Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Regent Surgical Health Topco, L.P. | — | Medical Devices | Series B | $23.7M | $498.4M | 2021 |
| Dilithium Networks Inc | — | Telecommunications | Series A | $12.9M | $26.3M | 2009 |
| Scioderm, Inc. | — | Pharmaceuticals | Series A | $9.0M | $278.7M | 2013 |
| Aegle Therapeutics Corp | — | Biotechnology | Series A | $7.0M | $1.2M | 2020 |
| Regent Surgical Health Intermediate Holdings, Inc. | — | Medical Devices | Seed | $4.0M | $86.6M | 2021 |
| St. Charles SC Holdings, LLC | — | Other Health Care | Seed | $1.3M | $31.9M | 2019 |
| Scioderm, LLC | — | Pharmaceuticals | Pre-Seed | $1.0M | $47.3M | 2013 |
| Hauppauge SC Holdings, LLC | — | Other Health Care | Pre-Seed | $995K | $30.6M | 2019 |
Robert Ryan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Ryan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Christopher Bishop | 4 | 6 |
| Matthew Lau | 4 | 5 |
| James O' Connor | 2 | 10 |
| Dennis Verzi | 2 | 2 |
| Patrick Minicus | 2 | 2 |
| Joseph T. Clark | 1 | 63 |
| Steve O'Hara | 1 | 6 |
| Glenn Miller | 1 | 5 |
| Elona Baum | 1 | 5 |
| Ralph Christoffersen | 1 | 5 |
| Chris Rust | 1 | 5 |
| Greg Miller | 1 | 5 |
| Roger J. Quy | 1 | 4 |
| Leon Moulder | 1 | 3 |
| Christopher J. Rust | 1 | 3 |
| Leon Moulder, Jr. | 1 | 3 |
| ROBERT COULL | 1 | 2 |
| Scott Braunstein | 1 | 2 |
| David Schimel | 1 | 2 |
| Travis Messina | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.